Oncology

Metastatic colorectal cancer prior to expanded RAS assessment: evidence from long-term outcome analysis of a real-life cohort within a dedicated colorectal cancer unit

Bertero L, Spadi R, Osella-Abate S, Mariani S, Castellano I, Gambella A, Racca P, Morino M, Cassoni P

World J Surg Oncol. 2020; 18: 65. Published online 2020 Apr 2. doi: 10.1186/s12957-020-01844-5

2020

Abstract

Background

Molecular assessment and treatment of metastatic colorectal cancer (mCRC) quickly evolved during the last decades, hampering longitudinal evaluation of prognostic markers. The aim of this study was to evaluate prognostic predictors of long-term survival in a retrospective series of mCRC, treated prior to the expanded RAS assessment era.

Methods

mCRC cases treated at the Città della Salute e della Scienza University Hospital (Turin, Italy) between January 2004 and December 2012 were evaluated, including cases with ≥ 5-year follow-up only. Long-term survival was defined as an overall survival (OS) ≥ 4 years based on the observed OS interquartile range values. Univariate/multivariate Cox proportional hazards regression models were performed to assess the prognostic significance of the clinical/biological features, while binary logistic regression models were used to verify their associations with long-term survival.

Results

Two hundred and forty-eight mCRC cases were included and analyzed. Sixty out of two hundred and forty-eight (24%) patients were long-term survivors. Univariate binary logistic regression analysis demonstrated a significant association between long-term survival and age at diagnosis < 65 (OR = 2.28, p = 0.007), single metastatic site (OR = 1.89, p = 0.039), surgical resection of metastases (OR = 5.30, p < 0.001), local non-surgical treatment of metastases (OR = 4.74, p < 0.001), and a bevacizumab-including first-line treatment schedule (OR = 2.19, p = 0.024). Multivariate binary logistic regression analysis confirmed the prognostic significance of surgical resection of metastases (OR = 3.96, p < 0.001), local non-surgical treatment of metastases (OR = 3.32, p = 0.001), and of bevacizumab-including first-line treatment schedule (OR = 2.49, p = 0.024).

Conclusion

Long-term survival could be achieved in a significant rate of patients with mCRC even in an era of limited molecular characterization. Local treatment of metastases proved to be a significant predictor of long-term survival.

 

NTRK Fusions in Central Nervous System Tumors: A Rare, but Worthy Target

Gambella A, Senetta R, Collemi G, Vallero SG, Monticelli M, Cofano F, Zeppa P, Garbossa D, Pellerino A, Rudà R, Soffietti R, Fagioli F, Papotti M, Cassoni P, Bertero L.

Int J Mol Sci. 2020 Jan 23;21(3):753. doi: 10.3390/ijms21030753.

2020

Abstract

The neurotrophic tropomyosin receptor kinase (NTRK) genes (NTRK1, NTRK2, and NTRK3) code for three transmembrane high-affinity tyrosine-kinase receptors for nerve growth factors (TRK-A, TRK-B, and TRK-C) which are mainly involved in nervous system development. Loss of function alterations in these genes can lead to nervous system development problems; conversely, activating alterations harbor oncogenic potential, promoting cell proliferation/survival and tumorigenesis. Chromosomal rearrangements are the most clinically relevant alterations of pathological NTRK activation, leading to constitutionally active chimeric receptors. NTRK fusions have been detected with extremely variable frequencies in many pediatric and adult cancer types, including central nervous system (CNS) tumors. These alterations can be detected by different laboratory assays (e.g., immunohistochemistry, FISH, sequencing), but each of these approaches has specific advantages and limitations which must be taken into account for an appropriate use in diagnostics or research. Moreover, therapeutic targeting of this molecular marker recently showed extreme efficacy. Considering the overall lack of effective treatments for brain neoplasms, it is expected that detection of NTRK fusions will soon become a mainstay in the diagnostic assessment of CNS tumors, and thus in-depth knowledge regarding this topic is warranted.

 

Cold formalin fixation guarantees DNA integrity in formalin fixed paraffin embedded tissues: premises for a better quality of diagnostic and experimental pathology with a specific impact on breast cancer

Berrino E, Miglio U, Annaratone L, Maldi E, Piccinelli C, Peano E, Balmativola D, Cassoni P, Pisacane A, Sarotto I, Venesio T, Sapino A, Marchiò C.

Frontiers in Oncology - Women's Cancer - in press

2020

CUTseq is a versatile method for preparing multiplexed DNA sequencing libraries from low-input samples

 2019 Oct 18;10(1):4732. doi: 10.1038/s41467-019-12570-2

Author information

1
Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, SE-17165, Sweden.
2
Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20954, Lublin, Poland.
3
Pathology Unit, Candiolo Cancer Institute, FPO-IRCCS, 10060, Candiolo (TO), Italy.
4
Department of Medical Sciences, University of Turin, Turin, Italy.
5
Department of Oncology and Pathology, Karolinska Institutet, Stockholm, SE-17177, Sweden.
6
Department of Clinical Pathology, Karolinska University Laboratory, 17176, Stockholm, Sweden.
7
Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, SE-17165, Sweden. magda.bienko@ki.se.
8
Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, SE-17165, Sweden. nicola.crosetto@ki.se

 

2019

Abstract

Current multiplexing strategies for massively parallel sequencing of genomic DNA mainly rely on library indexing in the final steps of library preparation. This procedure is costly and time-consuming, because a library must be generated separately for each sample. Furthermore, library preparation is challenging in the case of fixed samples, such as DNA extracted from formalin-fixed paraffin-embedded (FFPE) tissues. Here we describe CUTseq, a method that uses restriction enzymes and in vitro transcription to barcode and amplify genomic DNA prior to library construction. We thoroughly assess the sensitivity and reproducibility of CUTseq in both cell lines and FFPE samples, and demonstrate an application of CUTseq for multi-region DNA copy number profiling within single FFPE tumor sections, to assess intratumor genetic heterogeneity at high spatial resolution. In conclusion, CUTseq is a versatile and cost-effective method for library preparation for reduced representation genome sequencing, which can find numerous applications in research and diagnostics.

 

Germline mutations and new copy number variants among 40 pediatric cancer patients suspected for genetic predisposition

Gambale A, Russo R, Andolfo I, Quaglietta L, De Rosa G, Contestabile V, De Martino L, Genesio R, Pignataro P, Giglio S, Capasso M, Parasole R, Pasini B, Iolascon A.

Clin Genet. 2019 Oct;96(4):359-365. doi: 10.1111/cge.13600. Epub 2019 Jul 15. PMID 31278746

 

2019

Author information

1
Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli Federico II, Naples, Italy.
2
CEINGE Biotecnologie Avanzate, Naples, Italy.
3
Azienda Ospedaliera di Rilievo Nazionale Santobono Pausilipon, S.C. Pediatria Oncologia, Dip. di Oncoematologia Pediatrica Napoli, Italy.
4
Biomedical Experimental and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.
5
SOD Genetica Medica, Azienda Ospedaliero-Universitaria Meyer, Florence, Italy.
6
IRCCS SDN, Naples, Italy.
7
Dipartimento di Scienze Mediche, Università degli Studi di Torino, Torino, Italy.

 

Abstract

Cancer predisposition syndromes (CPS) result from germline pathogenic variants, and they are increasingly recognized in the etiology of many pediatric cancers. Herein, we report the genetic/genomic analysis of 40 pediatric patients enrolled from 2016 to 2018. Our diagnostic workflow was successful in 50% of screened cases. Overall, the proportion of CPS in our case series is 10.9% (20/184) of enrolled patients. Interestingly, 12.5% of patients achieved a conclusive diagnosis through the analysis of chromosomal imbalance. Indeed, we observed germline microdeletions/duplications of regions encompassing cancer-related genes in 50% of patients undergoing array-CGH: EIF3H duplication in a patient with infantile desmoplastic astrocytoma and low-grade Glioma; SLFN11 deletion, SOX4 duplication, and PARK2 partial deletion in three neuroblastoma patients; a PTPRD partial deletion in a child diagnosed with glioblastoma multiforme. Finally, we identified two cases due to DICER1 germline mutations.

 

PAX8-GLIS3 gene fusion is a pathognomonic genetic alteration of hyalinizing trabecular tumors of the thyroid

Marchiò C1,2Da Cruz Paula A3Gularte-Merida R4Basili T4Brandes A4da Silva EM4Silveira C4Ferrando L4,5Metovic J6Maletta F6Annaratone L1,2Pareja F4Rubin BP7Hoschar AP7De Rosa G8La Rosa S9Bongiovanni M9Purgina B10Piana S11Volante M12Weigelt B4Reis-Filho JS13,14Papotti M15.

 2019 Dec;32(12):1734-1743. doi: 10.1038/s41379-019-0313-x. Epub 2019 Jul 4.

2019

Author information

1
Pathology Division, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.
2
Department of Medical Sciences, University of Turin, Torino, Italy.
3
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
4
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
5
Department of Internal Medicine, University of Genova, Genova, Italy.
6
Department of Oncology, University of Turin, at Città della Salute Hospital, Torino, Italy.
7
Department of Pathology, Cleveland Clinic, Cleveland, OH, USA.
8
Pathology Division, Mauriziano Hospital, Torino, Italy.
9
Service of Clinical Pathology, Lausanne University Hospital, Institute of Pathology, Lausanne, Switzerland.
10
Department of Pathology and Laboratory Medicine, Ottawa Hospital, ON, Canada.
11
Pathology Unit, Arcispedale Santa Maria Nuova, Azienda USL-IRCCS, Reggio Emilia, Italy.
12
San Luigi Gonzaga Hospital and Department of Oncology, University of Turin, Orbassano, Italy.
13
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. reisfilj@mskcc.org.
14
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. reisfilj@mskcc.org.
15
Department of Oncology, University of Turin, at Città della Salute Hospital, Torino, Italy. mauro.papotti@unito.it.

 

Abstract

The hyalinizing trabecular adenoma/tumor is a rare and poorly characterized follicular-derived thyroid neoplasm recently shown to harbor recurrent PAX8-GLIS1 or PAX8-GLIS3 gene fusions. Here we sought to define the repertoire of genetic alterations of hyalinizing trabecular tumors, and whether PAX8-GLIS3 fusions are pathognomonic for hyalinizing trabecular tumors. A discovery series of eight hyalinizing trabecular tumors was subjected to RNA-sequencing (n = 8), whole-exome sequencing (n = 3) or targeted massively parallel sequencing (n = 5). No recurrent somatic mutations or copy number alterations were identified in hyalinizing trabecular tumor, whereas RNA-sequencing revealed the presence of a recurrent genetic rearrangement involving PAX8 (2q14.1) and GLIS3 (9p24.2) genes in all cases. In this in-frame fusion gene, which comprised exons 1-2 of PAX8 and exons 3-11 of GLIS3, GLIS3 is likely placed under the regulation of PAX8. Reverse transcription RT-PCR and/or fluorescence in situ hybridization analyses of a validation series of 26 hyalinizing trabecular tumors revealed that the PAX8-GLIS3 gene fusion was present in all hyalinizing trabecular tumors (100%). No GLIS1 rearrangements were identified. Conversely, no PAX8-GLIS3 gene fusions were detected in a cohort of 237 control thyroid neoplasms, including 15 trabecular thyroid lesions highly resembling hyalinizing trabecular tumor from a morphological standpoint, as well as trabecular/solid follicular adenomas, solid/trabecular variants of papillary carcinoma, and Hurthle cell adenomas or carcinomas. Our data provide evidence to suggest that the PAX8-GLIS3 fusion is pathognomonic for hyalinizing trabecular tumors, and that the presence of the PAX8-GLIS3 fusion in thyroid neoplasms may be used as an ancillary marker for the diagnosis of hyalinizing trabecular tumor, thereby avoiding overtreatment in case of misdiagnoses with apparently similar malignant tumors.

 

Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine

 

Varamo C1,2Peraldo-Neia C3Ostano P4Basiricò M5Raggi C6,7Bernabei P8Venesio T9Berrino E10,11Aglietta M12,13Leone F14,15Cavalloni G16.

 2019 Apr 11;11(4). pii: E519. doi: 10.3390/cancers11040519.

2019

Author information

1
Department of Oncology, University of Turin, 10100 Torino, Italy. chiara.varamo@unito.it.
2
Laboratory of Tumor Inflammation and Angiogenesis, Department of Oncology, Center for Cancer Biology, KU Leuven, B3000 Leuven, Belgium. chiara.varamo@unito.it.
3
Cancer Genomics Lab, Fondazione Edo ed Elvo Tempia, 13900 Biella, Italy. caterina.peraldoneia@ircc.it.
4
Cancer Genomics Lab, Fondazione Edo ed Elvo Tempia, 13900 Biella, Italy. paola.ostano@gmail.com.
5
Division of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Torino, Italy. marco.basirico@ircc.it.
6
Center for Autoimmune Liver Diseases, Humanitas Clinical and Research Center, 20089 Rozzano, Italy. chiara.raggi@unifi.it.
7
Dept. Medicina Sperimentale e Clinica, Università di Firenze, 50100 Florence, Italy. chiara.raggi@unifi.it.
8
Flow Cytometry Center, Candiolo Cancer Institute FPO-IRCCS, 10060 Candiolo, Torino, Italy. paola.bernabei@ircc.it.
9
Molecular Pathology Lab, Unit of Pathology, Candiolo Cancer Institute FPO-IRCCS, 10060 Candiolo, Torino, Italy. tiziana.venesio@ircc.it.
10
Molecular Pathology Lab, Unit of Pathology, Candiolo Cancer Institute FPO-IRCCS, 10060 Candiolo, Torino, Italy. enrico.berrino@ircc.it.
11
Department of Medical Sciences, University of Turin, Corso Dogliotti 14, 10126 Turin, Italy. enrico.berrino@ircc.it.
12
Department of Oncology, University of Turin, 10100 Torino, Italy. massimo.aglietta@unito.it.
13
Division of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Torino, Italy. massimo.aglietta@unito.it.
14
Department of Oncology, University of Turin, 10100 Torino, Italy. francesco.leone@unito.it.
15
Division of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Torino, Italy. francesco.leone@unito.it.
16
Division of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Torino, Italy. giuliana.cavalloni@ircc.it.

 

Abstract

Intrahepatic cholangiocarcinoma (ICC) is one of the most lethal liver cancers. Late diagnosis and chemotherapy resistance contribute to the scarce outfit and poor survival. Resistance mechanisms are still poorly understood. Here, we established a Gemcitabine (GEM) resistant model, the MT-CHC01R1.5 cell line, obtained by a GEM gradual exposure (up to 1.5 µM) of the sensitive counterpart, MT-CHC01. GEM resistance was irreversible, even at high doses. The in vitro and in vivo growth was slower than MT-CHC01, and no differences were highlighted in terms of migration and invasion. Drug prediction analysis suggested that Paclitaxel and Doxycycline might overcome GEM resistance. Indeed, in vitro MT-CHC01R1.5 growth was reduced by Paclitaxel and Doxycycline. Importantly, Doxycycline pretreatment at very low doses restored GEM sensitivity. To assess molecular mechanisms underlying the acquisition of GEM resistance, a detailed analysis of the transcriptome in MT-CHC01R1.5 cells versus the corresponding parental counterpart was performed. Transcriptomic analysis showed that most up-regulated genes were involved in cell cycle regulation and in the DNA related process, while most down-regulated genes were involved in the response to stimuli, xenobiotic metabolism, and angiogenesis. Furthermore, additional panels of drug resistance and epithelial to mesenchymal transition genes (n = 168) were tested by qRT-PCR and the expression of 20 genes was affected. Next, based on a comparison between qRT-PCR and microarray data, a list of up-regulated genes in MT-CHC01R1.5 was selected and further confirmed in a primary cell culture obtained from an ICC patient resistant to GEM. In conclusion, we characterized a new GEM resistance ICC model that could be exploited either to study alternative mechanisms of resistance or to explore new therapies.

 

Tissues under-vacuum to overcome suboptimal preservation

Annaratone L1Marchiò C2Sapino A3.

 2019 Sep 25;52:104-109. doi: 10.1016/j.nbt.2019.05.007. Epub 2019 May 28.

 

2019

Author information

1
Department of Medical Sciences, University of Turin, Corso Dogliotti 14, 10126, Turin, Italy. Electronic address: laura.annaratone@unito.it.
2
Department of Medical Sciences, University of Turin, Corso Dogliotti 14, 10126, Turin, Italy; Candiolo Cancer Institute, FPO-IRCCS, Str. Provinciale 142 km 3.95, 10060, Candiolo (Turin), Italy. Electronic address: caterina.marchio@unito.it.
3
Department of Medical Sciences, University of Turin, Corso Dogliotti 14, 10126, Turin, Italy; Candiolo Cancer Institute, FPO-IRCCS, Str. Provinciale 142 km 3.95, 10060, Candiolo (Turin), Italy. Electronic address: anna.sapino@ircc.it.

 

Abstract

The accuracy of histopathological diagnosis is strictly reliant on adequate tissue preservation, which is completely dependent on pre-analytical variables. Among these variables, the time interval between the end of surgical excision to the onset of fixation (the cold ischemia time) may adversely affect preservation of tissue morphology, influencing the interpretation and reproducibility of diagnosis. During this time interval, the activation of enzymes may produce autolysis and degradation of antigens and nucleic acids, thus potentially affecting immunocytochemical and molecular results. Several studies have described under-vacuum at 4 °C storage of fresh surgical specimens as a safe and reliable method to control cold ischemia and preserve fresh tissues, as well as to standardize fixation times and implement tissue-banking. This review article gives a systematic overview of the advantages and drawbacks of the use of under-vacuum tissue preservation and cooling in surgical pathology, highlighting the impact this procedure may have on diagnostic and experimental pathology. It also documents our experience acquired within daily practice and national and international projects.

 

Prognostic impact of regression in patients with primary cutaneous melanoma >1 mm in thickness

 

Ribero S1Galli F2Osella-Abate S3Bertero L3Cattaneo L4Merelli B5Tondini C5Ghilardi L5De Giorgi V6Occelli M7Quaglino P1Cassoni P3Palmieri G8Massi D9Mandala M10, Queirolo P, Stanganelli I, Botti G, Caracò C, Chiarion Sileni V, Di Giacomo AM.; Italian Melanoma Intergroup.

 2019 Jan;80(1):99-105.e5. doi: 10.1016/j.jaad.2018.06.054. Epub 2018 Nov 14.

2019

Author information

1
Section of Dermatology, Medical Sciences Department, University of Turin, Turin, Italy.
2
Methodology for Clinical Research Laboratory, Instituto di Ricovero e Cura a Carattere Scientifico, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
3
Section of Surgical Pathology, Medical Sciences Department, University of Turin, Turin, Italy.
4
Unit of Pathology, Papa Giovanni XXIII Hospital, Bergamo, Italy.
5
Unit of Medical Oncology, Papa Giovanni XXIII Hospital, Bergamo, Italy.
6
Department of Dermatology, University of Florence, Florence, Italy.
7
Azienda Ospedaliera Santa Croce e Carle di Cuneo SC Oncologia, Cuneo, Italy.
8
Unit of Cancer Genetics, Institute of Biomolecular Chemistry, National Research Council, Sassari, Italy.
9
Division of Pathological Anatomy, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy.
10
Unit of Medical Oncology, Papa Giovanni XXIII Hospital, Bergamo, Italy. Electronic address: mariomandala@tin.it.

 

 

 

 


 

Abstract

Background: The impact of histologic regression on sentinel lymph node biopsy (SLNB) status and on clinical outcome is uncertain.

Objective: To investigate whether and to what extent regression <75% is able to predict SLNB status and clinical outcome of patients with melanoma >1-mm thick.

Methods: The study included patients with diagnoses given at 4 centers of the Italian Melanoma Intergroup. Univariate and multivariate Cox proportional hazard models stratified by center were used to analyze the effect of regression on disease-free interval and melanoma-specific survival.

Results: Out of 1182 patients given primary cutaneous melanoma diagnoses during 1998-2015 with a Breslow thickness >1 mm, 954 (304 with and 650 without regression) were included in the analysis. The proportion of patients with a positive SLNB was lower in patients with regression than without (24.4% vs 31.6%, chi-squared test P = .0368). At multivariate analysis, no association was detected between regression and disease-free interval (hazard ratio 1.11, 95% confidence interval 0.85-1.46; P = .4509) or melanoma-specific survival (hazard ratio 1.05, 95% confidence interval 0.77-1.44; P = .7600).

Limitation: Retrospective analysis.

Conclusion: In our series, regression was not an independent prognostic factor in primary cutaneous melanoma patients with Breslow thickness >1 mm whereas it was associated with a lower incidence of SLNB positivity.

ALK expression favorably impacts the prognosis of NRAS-mutated metastatic melanomas

Osella-Abate S1Mereu E2Pellegrino E2Bergaggio E2Ribero S3Bertero L2Lisa F3Fierro MT3Giulio Papotti M4Piva R2.

 2018 Dec;16(6):7091-7096. doi: 10.3892/ol.2018.9560. Epub 2018 Oct 9.

2018

Author information

  • Department of Medical Sciences, Pathology Unit, University of Torino, I-10126 Torino, Italy.
  • Department of Molecular Biotechnology and Health Sciences, Center for Experimental Research and Medical Studies, University of Torino, I-10126 Torino, Italy.
  • Department of Medical Sciences, Dermatology Unit, University of Torino, I-10126 Torino, Italy.
  • Department of Oncology, Pathology Unit, University of Torino, I-10126 Torino, Italy.

 

Abstract

Recent studies reported the expression of anaplastic lymphoma kinase (ALK) in malignant melanomas. The aim of this study was to investigate whether ALK expression is associated with specific clinical and molecular characteristics of melanoma metastases, and to evaluate its correlation with survival outcomes. Seventy-one patients with metastatic melanoma were investigated. Clinical features and survival outcomes were analyzed and correlated to ALK expression, as detected by immunohistochemistry and reverse transcription-quantitative polymerase chain reaction, and to the mutational status of BRAF, KRAS, NRAS, and PIK3CA. No translocations or ALK alternative isoforms were identified. ALK expression was mainly detected in NRAS mutated metastatic lesions. Interestingly, among NRAS-mutated patients, ALK positive samples displayed a significantly more favorable outcome in terms of disease specific survival, as compared to ALK negative ones. In conclusion, we suggest that ALK positive/NRAS mutated metastases represent a specific subset of metastatic melanomas, associated with a better prognosis. Validation of these observations in larger cohorts could contribute to understand the molecular events cooperating to melanoma progression, in addition to open new perspectives in the clinical and therapeutic management of this subgroup of patients.

 

Pagine